Abstract
A new controlled delivery system has been developed for ropinirole (RP) for the treatment of Parkinson´s Disease (PD) consisting in PLGA microparticles (MPs) which exhibited in vitro constant release of RP (78.23 µg/day/10 mg MPs) for 19 days. The neuroprotective effects of RP released from MPs were evaluated in SKN-AS cells after exposure to rotenone (20 µM). Cell apoptosis was significantly reduced by RP (100-120 µM). Daily doses of rotenone (2 mg/kg) given i.p. to rats induced neuronal and behavioral changes similar to those of PD. After 15 days, animals received RP in saline (1 mg/kg/day for 45 days) or as MPs at two dose levels (amount of MPs equivalent to 7.5 mg/kg or 15 mg/kg RP given on days 15 and 30). Brain immunochemistry (Nisslstaining, GFAP and TH immunohistochemistry) and behavioral testing (catalepsy, akinesia, rotarod and swim test) showed that animals receiving RP either in solution or encapsulated within the MPs reverted the PD symptoms with the best results obtained in animals receiving RP microspheres at the highest dose assayed, thereby confirming the potential therapeutic interest of the new RP delivery system.
Keywords: Ropinirole, PLGA, microspheres, rotenone, Parkinson´s disease, brain immunochemistry.
Current Pharmaceutical Design
Title:Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism
Volume: 23 Issue: 23
Author(s): Sofia Negro, Liudmilla Boeva, Karla Slowing, Ana Fernandez-Carballido, Luis Garcia-García and Emilia Barcia*
Affiliation:
- Dpto. Farmacia y Tecnologia Farmaceutica, Facultad de Farmacia, Plaza Ramon y Cajal s/n, 28040 Madrid,Spain
Keywords: Ropinirole, PLGA, microspheres, rotenone, Parkinson´s disease, brain immunochemistry.
Abstract: A new controlled delivery system has been developed for ropinirole (RP) for the treatment of Parkinson´s Disease (PD) consisting in PLGA microparticles (MPs) which exhibited in vitro constant release of RP (78.23 µg/day/10 mg MPs) for 19 days. The neuroprotective effects of RP released from MPs were evaluated in SKN-AS cells after exposure to rotenone (20 µM). Cell apoptosis was significantly reduced by RP (100-120 µM). Daily doses of rotenone (2 mg/kg) given i.p. to rats induced neuronal and behavioral changes similar to those of PD. After 15 days, animals received RP in saline (1 mg/kg/day for 45 days) or as MPs at two dose levels (amount of MPs equivalent to 7.5 mg/kg or 15 mg/kg RP given on days 15 and 30). Brain immunochemistry (Nisslstaining, GFAP and TH immunohistochemistry) and behavioral testing (catalepsy, akinesia, rotarod and swim test) showed that animals receiving RP either in solution or encapsulated within the MPs reverted the PD symptoms with the best results obtained in animals receiving RP microspheres at the highest dose assayed, thereby confirming the potential therapeutic interest of the new RP delivery system.
Export Options
About this article
Cite this article as:
Negro Sofia, Boeva Liudmilla, Slowing Karla, Fernandez-Carballido Ana, Garcia-García Luis and Barcia Emilia*, Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism, Current Pharmaceutical Design 2017; 23 (23) . https://dx.doi.org/10.2174/1381612822666160928145346
DOI https://dx.doi.org/10.2174/1381612822666160928145346 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders
Current Alzheimer Research Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences Radiotracers in Oncology
Current Radiopharmaceuticals Preclinical Data Supporting/Refuting the Use of Hypericum perforatum in the Treatment of Depression
CNS & Neurological Disorders - Drug Targets Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Animal Models for Testing Anti-Prion Drugs
Current Topics in Medicinal Chemistry Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Current Pharmaceutical Design Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Protein Folding and Misfolding, Endoplasmic Reticulum Stress in Neurodegenerative Diseases: in Trace of Novel Drug Targets
Current Protein & Peptide Science A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Current Drug Discovery Technologies CD93 and Related Family Members: Their Role in Innate Immunity
Current Drug Targets Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
Current Medicinal Chemistry Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued)